PDS Planning Inc Purchases 25,662 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

PDS Planning Inc boosted its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 389.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 32,254 shares of the company’s stock after acquiring an additional 25,662 shares during the period. PDS Planning Inc’s holdings in Dr. Reddy’s Laboratories were worth $509,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its holdings in Dr. Reddy’s Laboratories by 423.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after acquiring an additional 1,507 shares during the last quarter. POM Investment Strategies LLC grew its holdings in Dr. Reddy’s Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after acquiring an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Dr. Reddy’s Laboratories by 461.0% in the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock worth $40,000 after acquiring an additional 2,093 shares during the last quarter. Allworth Financial LP grew its holdings in Dr. Reddy’s Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after acquiring an additional 2,230 shares during the last quarter. Finally, Sierra Ocean LLC bought a new stake in Dr. Reddy’s Laboratories in the 4th quarter worth $43,000. Institutional investors own 3.85% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on RDY shares. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

Dr. Reddy’s Laboratories Trading Up 1.0 %

NYSE:RDY opened at $13.36 on Wednesday. Dr. Reddy’s Laboratories Limited has a 12 month low of $12.50 and a 12 month high of $16.89. The stock has a market cap of $11.15 billion, a price-to-earnings ratio of 21.27 and a beta of 0.48. The company has a 50-day moving average price of $13.78 and a 200-day moving average price of $14.74. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Equities analysts predict that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.